Document is current
Any future updates will be listed below
-
Authors
Iimura, Yohei https://orcid.org/0000-0002-3473-8244
Ishiguro, Hiroshi
Hashimoto, Hironobu
Nojima, Masanori
Oyamada, Shunsuke
Mori, Keita
Ariyoshi, Keisuke
Kuroda, Seiichiro
Hirakawa, Satoshi
Fujiwara, Noriko
Yokota, Tomoya
Zenda, Sadamoto
Matsuoka, Hiromichi
Boku, Narikazu
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Reseach (24ck0106978h0001)
The University of Tokyo
- License Information
-
More Information
Article History
Received: 24 March 2025
Accepted: 6 May 2025
First Online: 14 May 2025
Declarations
:
: Hiroshi Ishiguro received a research grant from AstraZenecaKK, ONO PHARMACEUTICAL CO., LTD., DAIICHI SANKYO COMPANY, LIMITED, CHUGAI PHARMACEUTICAL CO., LTD., NIPRO CORPORATION, Takeda Pharmaceutical Co., Ltd., MSD K.K., Eisai Co., Ltd.; Narikazu Boku received lecture fees from Bristol Myers Squibb, Eli Lilly & Co., TAIHO PHARMACEUTICAL, CO., LTD., Astellas Pharma Inc.; Yohei Iimura, Hironobu Hashimoto, Masanori Nojima, Shunsuke Oyamada, Keita Mori, Keisuke Ariyoshi, Seiichiro Kuroda, Satoshi Hirakawa, Noriko Fujiwara, Tomoya Yokota, Sadamoto Zenda, and Hiromichi Matsuoka have no conflict of interest.
: This protocol was reviewed and approved by the certified Clinical Research Review Board of the University of Tokyo (approval number: 2024505SP) prior to conducting the trial. This clinical trial was conducted in compliance with the Clinical Trials Act in Japan and was registered in the Japan Registry of Clinical Trials (jRCT) as jRCTs031240705.
: All patients were required to provide written informed consent.
: Not applicable.
: Personal information, such as name, address, and medical ID, will be not collected.
: The study will be initiated in April 2025. We expect to complete the recruitment by March 2027.
